藥明康德榮膺CDP氣候變化和水安全“雙A”評級 | Bilingual News

上海，2026年1月19日 – 藥明康德今日宣布，公司在2025年全球環境信息研究中心（CDP）評估中，在氣候變化和水安全兩個議題上均入選“A級”榜單。“A級”是CDP在相關領域授予的最高等級，這一認可充分體現了藥明康德在氣候變化和水資源管理方面的突出表現和對可持續發展的堅定承諾。

CDP作為一家全球性非營利組織，運營著全球唯一的獨立環境信息披露系統，協助企業、資本市場、城市等管理其環境影響。CDP的年度評估流程與國際主流環境框架和信息披露標準保持一致，被廣泛視為評估企業環境管理水平的權威標準。在本次評估中，藥明康德首次入選氣候變化“A級”榜單，并連續第二年榮登水安全“A級”榜單。

“同時入選CDP氣候變化和水安全‘A級’榜單，體現了藥明康德始終致力于推動醫藥領域的可持續創新。”藥明康德聯席首席執行官兼可持續發展委員會主席楊青博士表示：“作為全球醫藥和生命科學領域值得信賴的合作伙伴，藥明康德在助力客戶加速新藥和突破性療法問世的同時，持續將環境責任融入公司運營，致力于構建更健康、更可持續的未來。”

氣候變化和水資源管理策略是藥明康德踐行環境保護承諾的重要組成部分。公司積極識別和應對環境相關的風險與機遇，不斷強化環境管理體系，并切實保護運營基地及其周邊自然環境。同時，藥明康德圍繞多個關鍵環境管理事項設立了目標，并通過監測和評估，實現量化分析與定期精準復盤。

作為創新的賦能者、客戶信賴的合作伙伴以及全球健康產業的貢獻者，藥明康德和大多數客戶一樣，積極踐行對可持續發展的承諾。截至目前，公司連續五年獲得MSCI ESG領導力評級，并在最新的評估中首次獲得“AAA”最高評級；連續四年入選道瓊斯可持續發展指數（DJSI）；連續三年入選富時羅素社會責任指數系列；連續兩年獲得EcoVadis企業社會責任評級“金牌”認證。

此外，為進一步深化可持續發展承諾，藥明康德持續拓展全球責任實踐。公司溫室氣體減排近期目標成功通過了SBTi審核認證。同時，公司已加入聯合國全球契約組織（UNGC），承諾支持全球契約十項原則；并加入制藥供應鏈倡議（PSCI），成為PSCI供應商合作伙伴。

關于藥明康德

藥明康德（股票代碼：603259.SH/2359.HK）是全球醫藥及生命科學行業值得信賴的合作伙伴和重要貢獻者，致力于通過提供一體化、端到端的新藥研發和生產服務，推動全球醫藥健康創新。公司在亞洲、歐洲、北美等地均設有運營基地，依托獨特的“CRDMO”業務模式，不斷降低研發門檻，助力客戶提升研發效率，為患者帶來突破性的治療方案。目前，公司的賦能平臺正承載著來自全球30多個國家的約6,000家合作伙伴的研發創新項目，致力于將更多新藥、好藥帶給全球病患，早日實現“讓天下沒有難做的藥，難治的病”的愿景。更多信息，請訪問公司網站：www.wuxiapptec.com

WuXi AppTec Receives Double “A” Rating from CDP for Climate Change and Water Security Leadership

SHANGHAI, January 18, 2026 - WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized on the “A List” for leadership in corporate transparency and performance across both Climate Change and Water Security by CDP (Carbon Disclosure Project). This recognition, which represents CDP’s highest rating in each category, underscores WuXi AppTec’s achievements in climate change and water resource management and its ongoing commitment to sustainable development.

CDP is a global non-profit that runs the world’s only independent environmental disclosure system for companies, capital markets, cities, states and regions to manage their environmental impacts. Its annual assessment process, aligned with major environmental frameworks and disclosure standards, is renowned as a global benchmark for evaluating companies’ environment-related activities. In the latest assessment, WuXi AppTec was named to CDP’s “A List” for Climate Change for the first time and included on CDP’s “A List” for Water Security for the second consecutive year.

“Earning CDP’s ‘A’ rating for both Climate Change and Water Security reflects WuXi AppTec’s unwavering commitment to sustainable pharmaceutical innovation,” said Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of WuXi AppTec’s Sustainability Committee. “As a trusted partner to the global pharmaceutical and life sciences industry, we are dedicated to advancing life-saving therapies while integrating environmental stewardship throughout our operations.”

Climate change and water resource management strategies are core components of WuXi AppTec’s commitment to environmental protection. The Company actively addresses environmental risks and opportunities, continuously strengthens its environmental management systems, and effectively safeguards its operational sites and the surrounding natural environment. WuXi AppTec has set targets across multiple key environmental management areas and monitors progress to enable quantitative analysis and regular, precise reviews.

As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec integrates sustainability throughout its operations in alignment with the values of its customers and partners. The Company’s leadership in sustainability has been recognized by several prestigious organizations, notably receiving the MSCI ESG Leadership Rating for five consecutive years and achieving its first AAA rating in the most recent assessment. It has also been included in the Dow Jones Sustainability Index (DJSI) for four consecutive years and the FTSE4Good Index Series for three consecutive years. Additionally, the Company has received a Gold Medal in sustainability from EcoVadis for the second consecutive year.

Furthering its sustainability commitments, WuXi AppTec has received validation from the Science Based Targets initiative (SBTi) for its near-term emissions reduction targets. The Company is also a participant in the United Nations Global Compact (UNGC), supporting its ten principles, and serves as a supplier partner to the Pharmaceutical Supply Chain Initiative (PSCI).

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.

免責聲明：本文僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導，請前往正規醫院就診。

版權說明：歡迎個人轉發至朋友圈，謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”，獲取轉載須知。